360 S&P 500 stocks underperformed in 2024, but analysts recommend Pfizer and Realty Income in 2025.

From Nasdaq: 2024-12-29 05:15:00

The stock market has seen a strong year with the S&P 500 up 24.5%, led by tech giants. However, market breadth has been poor, with the Invesco S&P 500 Equal Weight ETF only up 12%. There are opportunities to find bargains among the 360 S&P 500 stocks with returns below average. Pfizer’s stock is down 7.5% in 2024 due to declining vaccine demand, but analysts are optimistic about its future drug development and revenue growth forecast. Pfizer also offers a 6.5% dividend yield.

Realty Income, a commercial REIT, has seen its stock price drop by 8.3% in 2024 due to rising interest rates. Despite this, the company has a strong balance sheet and a track record of paying monthly dividends for over 54 years. Realty Income is diversifying its investments and has a 6% dividend yield. Investors are being urged to consider “Double Down” stock recommendations for potentially lucrative opportunities with companies like Nvidia, Apple, and Netflix.



Read more at Nasdaq: 360 Stocks in the S&P 500 Underperformed the Benchmark’s 2024 Gain of 24%. Here’s 2 High-Yielding S&P 500 Stocks to Buy in 2025, According to Wall Street.